Pre-exposure prophylaxis for HIV prevention: Ready for prime time in South Africa?

South African Medical Journal

Volumn 103, Issue 8, 2013, Pages 515-516

  Eakle, R ^a   Venter, W D F ^b   Rees, H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; CONDOM; COST EFFECTIVENESS ANALYSIS; DRIVER; DRUG EFFICACY; EDITORIAL; HEALTH CARE DELIVERY; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEN WHO HAVE SEX WITH MEN; PATIENT COMPLIANCE; PROPHYLAXIS; PROSTITUTION; SOCIAL STIGMA; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; SOUTH AFRICA;

EID: 84880851428     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.6937     Document Type: Editorial

References (29)

1. UNAIDS. UNAIDS World AIDS Day Report 2011. 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf (accessed 17 January 2013).
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367(5):423-434. [http://dx.doi. org/10.1056/NEJMoa1110711]
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410. [http://dx.doi.org/10.1056/ NEJMoa1108524]
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-2599. [http://dx.doi.org/10.1056/ NEJMoa1011205]
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168- 1174. [http://dx.doi.org/10.1126/science.1193748]
6. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-2090. [http://dx.doi.org/10.1016/ S0140-6736(13)61127-7]
7. Centers for Disease Control. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep 2012;61(31):586-589. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm?s_ cid=mm6131a2_w (accessed 17 January 2013).
8. Centers for Disease Control. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60(3):65-68. http:// www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm (accessed 17 January 2013).
9. Southern African HIV Clinicians Society Consensus Committee. Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. Southern African Journal of HIV Medicine 2012;13(2):40-55.
10. World Health Organization. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. 2012. http://www. who.int/hiv/pub/guidance_prep/en/index.html (accessed 17 January 2013).
11. South African National AIDS Council. Strategic Plan on HIV, STIs and TB 2012-2016. 2012. http://www.sanac.org.za/files/uploaded/NSP%2027Jan2012%20Full%20APPROVED%2010Feb2012%20 Web.pdf (accessed 17 January 2013).
12. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367(5):411-422. [http://dx.doi.org/10.1056/NEJMoa1202614]
13. Microbicides Trial Network. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. 2011. http://www.mtnstopshiv.org/node/3619 (accessed 28 March 2013).
14. Microbicides Trial Network. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. 2011. http://www.mtnstopshiv.org/node/3909 (accessed 28 March 2013).
15. Marrazzo J, Ramjee G, Palanee T, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Presented at HIV Prevention: ARV, Counseling, Contraception, and Condoms. Conference on Retroviruses and Opportunistic Infections, 4 March 2013, Atlanta, Ga. http://www.retroconference. org/2013b/Abstracts/47951.htm (accessed 28 March 2013).
16. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4(151):151ra125. [http:// dx.doi.org/10.1126/scitranslmed.3004006]
17. Prata N, Morris L, Mazive E, Vahidnia F, Stehr M. Relationship between HIV risk perception and condom use: Evidence from a population-based survey in Mozambique. International Family Planning Perspectives 2006;32(4):192-200. [http://dx.doi.org/10.1363/3219206]
18. Ahmed S, Lutalo T, Wawer M, et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: A population study in Rakai, Uganda. AIDS 2001;15(16):2171-2179. [http://dx.doi.org/10.1097/00002030-200111090-00013]
19. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation. Contraception 1995;51(5):283-288. [http://dx.doi.org/10.1016/0010- 7824(95)00074-K]
20. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS ONE 2011;6:e18165. [http://dx.doi.org/10.1371/journal.pone.0018165]
21. Desmond Tutu HIV Foundation. Key Populations, Key Responses: A Gap Analysis for Key Populations and HIV in South Africa, and Recommendations for the National Strategic Plan for HIV/AIDS, STIs and TB (2012-2016). 2011. http://www.desmondtutuhivfoundation.org.za/documents/Key- Populations-Key-Solutions-report.pdf (accessed 17 January 2013)
22. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS ONE 2012;7:e28238. [http://dx.doi.org/10.1371/journal.pone.0028238]
23. Carballo-Diéguez A, Frasca T, Balan I, Ibitoye M, Dolezal C. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. AIDS Behav 2012;16(7):1753- 1760. [http://dx.doi.org/10.1007/s10461-012-0274-2]
24. Mattson CL, Campbell RT, Bailey RC, Agot K, Ndinya-Achola JO, Moses S. Risk compensation is not associated with male circumcision in Kisumu, Kenya: A multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS ONE 2008;3:e2443. [http://dx.doi.org/10.1371/journal. pone.0002443]
25. Tripathi A, Whiteside O, Scanlon C, Duffus W. Perceptions and attitudes about pre-exposure prophylaxis (PrEP) among seronegative partners and the potential of sexual disinhibition associated with the use of PrEP. Presented at the XIX International AIDS Conference, 22-27 July 2012, Washington, DC.
26. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev 2012;24(5):408-421. [http://dx.doi.org/10.1521/aeap.2012.24.5.408]
27. Steinbrook R. Preexposure prophylaxis for HIV infection. JAMA 2012;308(9):1-2. [http://dx.doi. org/10.1001/jama.2012.9885]
28. Jay J, Gostin L. Ethical challenges of preexposure prophylaxis for HIV. JAMA 2012;308(9):1-2. [http:// dx.doi.org/10.1001/2012.jama.10158]
29. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: A systematic review of cost-effectiveness modelling studies. PLoS Med 2013;10(3):e1001401. [http://dx.doi.org/10.1371/journal.pmed.1001401]